{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:42:12Z","timestamp":1784115732258,"version":"3.55.0"},"reference-count":34,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Z141100002114050"],"award-info":[{"award-number":["Z141100002114050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese Military Health Care","award":["17BJZ08"],"award-info":[{"award-number":["17BJZ08"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: The co-incidence of multiple morbidities and polypharmacy is common amongst patients with atrial fibrillation (AF); however, data on their impact on clinical outcomes are scarce in Asian cohorts. Objective: To evaluate the impact of multimorbidity and polypharmacy on clinical outcomes and AF management among elderly Chinese patients. Methods: The ChiOTEAF registry is a prospective, multicenter nationwide study conducted from October 2014 to December 2018. Endpoints of interest were the composite outcome of all-cause death\/any thromboembolism (TE), all-cause death, cardiovascular death, TE events, major bleeding, as well as AF management. Results: The eligible cohort included 6341 individuals (mean age 74.7 \u00b1 10.7; 39.1% female), of whom 4644 (73.2%) had multimorbidity (defined as two or more chronic diseases), and 2262 (35.7%) were treated with five or more medications. There were 2775 (43.8%) patients on anticoagulant (OAC) use. On multivariate analysis, (i) multimorbidity was associated with a higher odds ratio of the composite outcome (OR: 2.04; 95% CI: 1.49\u20132.79), all-cause death (OR: 1.82; 95% CI: 1.31\u20132.54), cardiovascular death (OR: 2.05; 95% CI: 1.13\u20133.69), any TE (OR: 2.69; 95% CI: 1.29\u20135.62), and major bleeding (OR: 2.61; 95% CI: 1.25\u20135.45); (ii) polypharmacy was associated with a lower odds ratio of all-cause death (OR: 0.78; 95% CI: 0.63\u20130.96). The use of OAC was safe and was associated with a lower odds ratio of the composite outcome and all-cause death in all subgroups of patients. Conclusions: Multimorbidity and polypharmacy were common among elderly AF Chinese patients. Multimorbidity was an independent predictor of adverse clinical outcomes. The use of OAC was safe and significantly improved survival amongst AF patients with multimorbidity and polypharmacy.<\/jats:p>","DOI":"10.3390\/jcm11051370","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T08:37:16Z","timestamp":1646210236000},"page":"1370","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of Multimorbidity and Polypharmacy on Clinical Outcomes of Elderly Chinese Patients with Atrial Fibrillation"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6762-3187","authenticated-orcid":false,"given":"Agnieszka","family":"Kotalczyk","sequence":"first","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool L14 3PE, UK"},{"name":"Silesian Centre for Heart Diseases, Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Medical University of Silesia, 41-800 Zabrze, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7626-7751","authenticated-orcid":false,"given":"Yutao","family":"Guo","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool L14 3PE, UK"},{"name":"Sixth Medical Centre, Department of Pulmonary Vessel and Thrombotic Disease, Chinese PLA General Hospital, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutang","family":"Wang","sequence":"additional","affiliation":[{"name":"Second Medical Centre, Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool L14 3PE, UK"},{"name":"Silesian Centre for Heart Diseases, Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Medical University of Silesia, 41-800 Zabrze, Poland"},{"name":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, 9000 Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ChiOTEAF Registry Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1093\/eurheartj\/eht280","article-title":"Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060","volume":"34","author":"Krijthe","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Burdett, P., and Lip, G.Y.H. (2020). Atrial Fibrillation in the United Kingdom: Predicting Costs of an Emerging Epidemic Recognising and Forecasting the Cost Drivers of Atrial Fibrillation-related costs. Eur. Heart J. Qual. Care Clin. Outcomes, qcaa093.","DOI":"10.1093\/ehjqcco\/qcaa093"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e14042","DOI":"10.1111\/ijcp.14042","article-title":"Prevalence\/incidence of atrial fibrillation based on integrated medical\/pharmacy claims, and association with co-morbidity profiles\/multi-morbidity in a large US adult cohort","volume":"75","author":"Lip","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/07853890.2020.1799241","article-title":"Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: Insights from the BALKAN-AF survey","volume":"53","author":"Simovic","year":"2021","journal-title":"Ann. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","article-title":"Epidemiology of multimorbidity and implications for health care, research, and medical education: A cross-sectional study","volume":"380","author":"Barnett","year":"2012","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Abu, H.O., Saczynski, J., Mehawej, J., Paul, T., Awad, H., Bamgbade, B.A., Pierre-Louis, I.C., Tisminetzky, M., Kiefe, C.I., and Goldberg, R.J. (2020). Multimorbidity, physical frailty, and self-rated health in older patients with atrial fibrillation. BMC Geriatr., 20.","DOI":"10.1186\/s12877-020-01755-w"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.mayocp.2019.06.012","article-title":"Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use","volume":"94","author":"Proietti","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"f329","DOI":"10.1093\/europace\/eux322","article-title":"Multimorbidity and co-morbidity in atrial fibrillation and effects on survival: Findings from UK Biobank cohort","volume":"20","author":"Jani","year":"2018","journal-title":"Europace"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e014932","DOI":"10.1161\/JAHA.119.014932","article-title":"Comprehensive Management with the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients with Atrial Fibrillation: A Post Hoc Ancillary Analysis from the AFFIRM Trial","volume":"9","author":"Proietti","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e020191","DOI":"10.1136\/bmjopen-2017-020191","article-title":"Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: Protocol for a prospective, observational nationwide cohort study","volume":"8","author":"Guo","year":"2018","journal-title":"BMJ Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/gerona\/glq208","article-title":"The measurement of multiple chronic diseases\u2014A systematic review on existing multimorbidity indices","volume":"66","author":"Diederichs","year":"2011","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/13814789609162146","article-title":"Comorbidity or multimorbidity","volume":"2","author":"Buntinx","year":"1996","journal-title":"Eur. J. Gen. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2125.2006.02744.x","article-title":"Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems","volume":"63","author":"Viktil","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_18","first-page":"308","article-title":"A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: Baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry","volume":"16","author":"Lip","year":"2014","journal-title":"EP Eur."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-7525-8-13","article-title":"A review of health utilities using the EQ-5D in studies of cardiovascular disease","volume":"8","author":"Dyer","year":"2010","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","article-title":"Estimating an EQ-5D-5L Value Set for China","volume":"20","author":"Luo","year":"2017","journal-title":"Value Health"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/joa3.12608","article-title":"One-year Follow-up Results of the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry","volume":"37","author":"Guo","year":"2021","journal-title":"J. Arrhythm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00392-015-0936-y","article-title":"Polypharmacy and major adverse events in atrial fibrillation: Observations from the AFFIRM trial","volume":"105","author":"Proietti","year":"2016","journal-title":"Clin. Res. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kozie\u0142, M., Teutsch, C., Halperin, J.L., Rothman, K.J., Diener, H.-C., Ma, C.-S., Marler, S., Lu, S., Gurusamy, V.K., and Huisman, M.V. (2021). Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0249524"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ahj.2014.02.003","article-title":"Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)","volume":"167","author":"Steinberg","year":"2014","journal-title":"Am. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Guo, Y., Kotalczyk, A., Imberti, J.F., Wang, Y., and Lip, G.Y.H. (2021). Poor adherence to guideline-directed anticoagulation in elderly Chinese patients with atrial fibrillation. A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. Eur. Heart J. Qual. Care Clin. Outcomes, qcab054.","DOI":"10.1093\/ehjqcco\/qcab054"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ehjqcco\/qcaa070","article-title":"Treatment of Older Patients with Atrial Fibrillation by Morbidity Burden","volume":"8","author":"Rasmussen","year":"2020","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41569-020-00459-3","article-title":"Stroke prevention strategies in high-risk patients with atrial fibrillation","volume":"18","author":"Kotalczyk","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_28","first-page":"i2868","article-title":"Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: Post hoc analysis of the ARISTOTLE trial","volume":"353","author":"Brouwer","year":"2016","journal-title":"BMJ"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.amjcard.2021.03.024","article-title":"Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial)","volume":"149","author":"Millenaar","year":"2021","journal-title":"Am. J. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ahj.2018.09.017","article-title":"Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial","volume":"208","author":"Alexander","year":"2019","journal-title":"Am. Heart J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1007\/s12325-021-01724-8","article-title":"Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity","volume":"38","author":"Deitelzweig","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: An integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Romiti, G.F., Pastori, D., Rivera-Caravaca, J.M., Ding, W.Y., Gue, Y.X., Menichelli, D., Gumprecht, J., Kozie\u0142, M., Yang, P.-S., and Guo, Y. (2021). Adherence to the \u201cAtrial Fibrillation Better Care\u201d Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic Review and Meta-Analysis of 285,000 Patients. Thromb. Haemost.","DOI":"10.1093\/europace\/euab116.290"},{"key":"ref_34","first-page":"1612","article-title":"2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Eur. Pacing"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/5\/1370\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:30:35Z","timestamp":1760135435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/5\/1370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["jcm11051370"],"URL":"https:\/\/doi.org\/10.3390\/jcm11051370","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,2]]}}}